Protein engineering definition

In cases where a protein is derived from a source that is not known lu be allergenic, it is not possible to predict definitively allergenic potential. While it is unlikely that a new protein that occurs in very low concentrations in food will be an allergen (as is ihe case for most proteins introduced via genetic engineering at this time), developers have taken steps to minimize... 

Insulin is a complex protein molecule produced by the pancreas in all vertebrates. This hormone regulates carbohydrate metabolism. Inability to produce insulin results in diabetes mellitus. Diabetes is treated by injections of insulin. Given the law of definite proportion, would you expect any differences in chemical activity between human insulin extracted from pancreatic tissue and human insulin produced by genetically engineered bacteria Why or why not ... 

The main general consideration that can be stated so far is 1) the smoothness of the separations 2) the absence of cell prelabeling and 3) the development of biocompatible instrumentation, which allows subpopulation lineage to be produced, which are not only usable for fundamental studies such as differentiation pathways or apoptosis studies, but also for transplantation or genetic engineering. One must have in mind that the cell is definitively the place, home, and native localization of genes and proteins. The possibility of rapid, nondestructive separation, purification, and characterization of cells (cellulomics) opens fabulous dimensions for proteomics and genomics. 

By definition, patches that significantly contribute to protein-water interfacial tension must translate into hot spots for protein-protein associations. Hence the laborious alanine scanning may be effectively replaced by a direct computational identification of patches of interfacial tension in the free subunits. This computational advance will no doubt simplify the engineering of therapeutic interference with protein-protein associations. 

Mammalian cells allow the production of complex biopharmaceutical proteins. Advances in the generation of stable recombinant clones, media formulation, and process and fermentor design have significantly increased yields over the past two decades. Exciting networks across the pro-teome and transcriptome are elucidated that show the enormous potential still hidden in mammalian cells. The near future will definitely show further improvement with cell lines specifically designed and metabolically engineered for industrial-scale production of biopharmaceuticals. 

In the case of rapamycin, it was possible to demonstrate that TOR is the target using a dominant mutant of TOR that is resistant to FKBP-rapamycin inhibition. These resistance mutations are the single most definitive means of demonstrating the phenotypically relevant target of a small molecule. Unfortunately, the availability of resistance mutations can be limiting attempts to engineer such a mutation may adversely affect the function of the protein... 

---